References
1. Franz CC, Egger S, Born C, Rätz Bravo AE, Krähenbühl S. Potential
drug-drug interactions and adverse drug reactions in patients with liver
cirrhosis. European journal of clinical pharmacology 2012;68:179-188.
2. Franz CC, Hildbrand C, Born C, Egger S, Rätz Bravo AE, Krähenbühl S.
Dose adjustment in patients with liver cirrhosis: impact on adverse drug
reactions and hospitalizations. European journal of clinical
pharmacology 2013;69:1565-1573.
3. Rodighiero V. Effects of liver disease on pharmacokinetics. Clinical
pharmacokinetics 1999;37:399-431.
4. Nevzorova YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J. Animal models
for liver disease–A practical approach for translational research.
Journal of hepatology 2020;73:423-440.
5. Guillouzo A. Liver cell models in in vitro toxicology. Environmental
health perspectives 1998;106:511-532.
6. Du Y, Polacheck WJ, Wells RG: Bile Duct-on-a-Chip. In:
Organ-on-a-Chip: Springer, 2022; 57-68.
7. Hassan S, Sebastian S, Maharjan S, Lesha A, Carpenter A-M, Liu X, Xie
X, et al. Liver-on-a-chip models of fatty liver disease. Hepatology
(Baltimore, Md.) 2020;71:733.
8. Melgert BN, Olinga P, Weert B, Slooff MJ, Meijer DK, Poelstra K,
Groothuis GM. Cellular distribution and handling of liver-targeting
preparations in human livers studied by a liver lobe perfusion. Drug
metabolism and disposition 2001;29:361-367.
9. Schreiter T, Marquitan G, Darnell M, Sowa J-P, Bröcker-Preuss M,
Andersson TB, Baba HA, et al. An ex vivo perfusion system emulating in
vivo conditions in noncirrhotic and cirrhotic human liver. Journal of
Pharmacology and Experimental Therapeutics 2012;342:730-741.
10. Villeneuve JP, Huet PM, Gariepy L, Fenyves D, Willems B, Cǒté J,
Lapointe R, et al. Isolated perfused cirrhotic human liver obtained from
liver transplant patients: a feasibility study. Hepatology
1990;12:257-263.
11. van Rijn R, Schurink IJ, de Vries Y, van den Berg AP, Cortes
Cerisuelo M, Darwish Murad S, Erdmann JI, et al. Hypothermic machine
perfusion in liver transplantation—a randomized trial. New England
Journal of Medicine 2021;384:1391-1401.
12. Stopfer P, Giessmann T, Hohl K, Hutzel S, Schmidt S, Gansser D,
Ishiguro N, et al. Optimization of a drug transporter probe cocktail:
potential screening tool for transporter‐mediated drug–drug
interactions. British journal of clinical pharmacology
2018;84:1941-1949.
13. de Vries Y, Matton AP, Nijsten MW, Werner MJ, van den Berg AP, de
Boer MT, Buis CI, et al. Pretransplant sequential hypo‐and normothermic
machine perfusion of suboptimal livers donated after circulatory death
using a hemoglobin‐based oxygen carrier perfusion solution. American
journal of transplantation 2019;19:1202-1211.
14. Brüggenwirth IM, van Leeuwen OB, Porte RJ, Martins PN. The emerging
role of viability testing during liver machine perfusion. Liver
Transplantation 2021.
15. Mergental H, Stephenson BT, Laing RW, Kirkham AJ, Neil DA, Wallace
LL, Boteon YL, et al. Development of clinical criteria for functional
assessment to predict primary nonfunction of high‐risk livers using
normothermic machine perfusion. Liver Transplantation 2018;24:1453-1469.
16. van Leeuwen OB, de Vries Y, Fujiyoshi M, Nijsten MW, Ubbink R,
Pelgrim GJ, Werner MJ, et al. Transplantation of high-risk donor livers
after ex situ resuscitation and assessment using combined hypo-and
normothermic machine perfusion: a prospective clinical trial. Annals of
surgery 2019;270:906-914.
17. Boteon YL, Laing RW, Schlegel A, Wallace L, Smith A, Attard J,
Bhogal RH, et al. Combined hypothermic and normothermic machine
perfusion improves functional recovery of extended criteria donor
livers. Liver transplantation 2018;24:1699-1715.
18. Eshmuminov D, Becker D, Bautista Borrego L, Hefti M, Schuler MJ,
Hagedorn C, Muller X, et al. An integrated perfusion machine preserves
injured human livers for 1 week. Nature biotechnology 2020;38:189-198.
19. Op den Dries S, Karimian N, Sutton M, Westerkamp A, Nijsten M, Gouw
A, Wiersema‐Buist J, et al. Ex vivo normothermic machine perfusion and
viability testing of discarded human donor livers. American Journal of
Transplantation 2013;13:1327-1335.
20. Bosch J, García-Pagán JC. Complications of cirrhosis. I. Portal
hypertension. Journal of hepatology 2000;32:141-156.
21. Stevens LJ, Zhu AZ, Chothe PP, Chowdhury SK, Donkers JM, Vaes WH,
Knibbe CA, et al. Evaluation of normothermic machine perfusion of
porcine livers as a novel preclinical model to predict biliary clearance
and transporter-mediated drug-drug interactions using statins. Drug
Metabolism and Disposition 2021;49:780-789.
22. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U,
Knutson L, et al. Biliary secretion of rosuvastatin and bile acids in
humans during the absorption phase. European journal of pharmaceutical
sciences 2006;29:205-214.
23. Hebert MF. Impact of pregnancy on maternal pharmacokinetics of
medications. Clinical pharmacology during pregnancy 2013:17-39.
24. Rane A, Wilkinson G, Shand D. Prediction of hepatic extraction ratio
from in vitro measurement of intrinsic clearance. Journal of
Pharmacology and Experimental Therapeutics 1977;200:420-424.
25. Delco F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S. Dose
adjustment in patients with liver disease. Drug safety 2005;28:529-545.
26. Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan
A. A semi-mechanistic model to predict the effects of liver cirrhosis on
drug clearance. Clinical pharmacokinetics 2010;49:189-206.
27. Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz
E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in
healthy adult male volunteers. Clinical therapeutics 2003;25:2822-2835.
28. Iisalo E. Clinical pharmacokinetics of digoxin. Clinical
pharmacokinetics 1977;2:1-16.
29. Doherty JE, Flanigan W, Murphy M, Bulloch R, Dalrymple G, Beard O,
Perkins W, et al. Tritiated digoxin: XIV. Enterohepatic circulation,
absorption, and excretion studies in human volunteers. Circulation
1970;42:867-873.
30. Ben-Itzhak J, Bassan HM, Shor R, Lanir A. Digoxin quinidine
interaction: a pharmacokinetic study in the isolated perfused rat liver.
Life sciences 1985;37:411-415.
31. Beermann B, Dalen E, Lindström B, Rosen A. On the fate of furosemide
in man. European journal of clinical pharmacology 1975;9:57-61.
32. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong J, Furlong TJ,
et al. Clinical pharmacokinetics of metformin. Clinical pharmacokinetics
2011;50:81-98.
33. Erlinger S. Bile secretion. British medical bulletin
1992;48:860-876.
34. Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S,
Maeda K, et al. Effect of OATP1B1 genotypes on plasma concentrations of
endogenous OATP1B1 substrates and drugs, and their association in
healthy volunteers. Drug metabolism and pharmacokinetics 2019;34:78-86.
35. Prueksaritanont T, Tatosian D, Chu X, Railkar R, Evers R, Chavez‐Eng
C, Lutz R, et al. Validation of a microdose probe drug cocktail for
clinical drug interaction assessments for drug transporters and CYP3A.
Clinical Pharmacology & Therapeutics 2017;101:519-530.
36. Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata K-i, Watanabe
N, Ando O, et al. Comparative study of the dose-dependence of OATP1B
inhibition by rifampicin using probe drugs and endogenous substrates in
healthy volunteers. Pharmaceutical research 2018;35:1-13.
37. Eurotransplant. Transplants in 2021, by country, by donor type, by
organ type. In: Statistics Report Library; 2022.
38. Thakkar N, Slizgi JR, Brouwer KL. Effect of liver disease on hepatic
transporter expression and function. Journal of pharmaceutical sciences
2017;106:2282-2294.
39. Drozdzik M, Szelag‐Pieniek S, Post M, Zeair S, Wrzesinski M,
Kurzawski M, Prieto J, et al. Protein abundance of hepatic drug
transporters in patients with different forms of liver damage. Clinical
Pharmacology & Therapeutics 2020;107:1138-1148.
40. Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao
M, et al. Transporter expression in noncancerous and cancerous liver
tissue from donors with hepatocellular carcinoma and chronic hepatitis C
infection quantified by LC-MS/MS proteomics. Drug Metabolism and
Disposition 2018;46:189-196.
41. Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, et
al. Transporter expression in liver tissue from subjects with alcoholic
or hepatitis C cirrhosis quantified by targeted quantitative proteomics.
Drug Metabolism and Disposition 2016;44:1752-1758.
42. Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg
M, Monster-Simons MH, et al. Evaluating the safety and dosing of drugs
in patients with liver cirrhosis by literature review and expert
opinion. BMJ open 2016;6:e012991.
43. Clark T, Bau L, Dengu F, Voyce D, Carlisle R, Friend P, Coussios C.
Predicting clinical pharmacokinetics and toxicity of current and
emerging oncology therapeutics by normothermic perfusion of isolated
human-sized organs. In: AACR; 2021.
44. Goumard C, Turco C, Sakka M, Aoudjehane L, Lesnik P, Savier E, Conti
F, et al. Ex-Vivo Pharmacological Defatting of the Liver: A Review.
Journal of Clinical Medicine 2021;10:1253.
45. Mazilescu LI, Selzner M, Selzner N. Defatting strategies in the
current era of liver steatosis. JHEP Reports 2021;3:100265.
46. Rigo F, Navarro-Tableros V, De Stefano N, Calleri A, Romagnoli R: Ex
vivo normothermic hypoxic rat liver perfusion model: an experimental
setting for organ recondition and pharmacological intervention. In: In
Vitro Models for Stem Cell Therapy: Springer, 2021; 139-150.
47. Franzin R, Stasi A, Fiorentino M, Simone S, Oberbauer R, Castellano
G, Gesualdo L. Renal Delivery of Pharmacologic Agents During Machine
Perfusion to Prevent Ischaemia-Reperfusion Injury: From Murine Model to
Clinical Trials. Frontiers in Immunology 2021;12:2687.
48. Butler AJ, Rees MA, Wight DG, Casey ND, Alexander G, White DJ,
Friend PJ. Successful extracorporeal porcine liver perfusion for 72 hr1.
Transplantation 2002;73:1212-1218.
49. Liu Q, Nassar A, Buccini L, Iuppa G, Soliman B, Pezzati D, Hassan A,
et al. Lipid metabolism and functional assessment of discarded human
livers with steatosis undergoing 24 hours of normothermic machine
perfusion. Liver Transplantation 2018;24:233-245.
50. Vogel T, Brockmann JG, Pigott D, Neil DA, Muthusamy ASR, Coussios
CC, Friend PJ. Successful transplantation of porcine liver grafts
following 48-hour normothermic preservation. PLoS One 2017;12:e0188494.
51. Sharma AK, Laubach VE. Protecting donor livers during normothermic
machine perfusion with stem cell EVs. Transplantation 2018;102:725.